• IMMUNE NETWORK
• /
• v.21 no.3
• /
• pp.22.1-22.17
• /
• 2021

Chitinase-3-like-1 (CHI3L1) is known to induce inflammation in the progression of allergic diseases. Previous our studies revealed that 2-({3-[2-(1-cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2-quinazolinyl}sulfanyl)-N-(4-ethylphenyl)butanamide (K284-6111; K284), the CHI3L1 inhibiting compound, has the anti-inflammatory effect on neuroinflammation. In this study, we investigated that K284 treatment could inhibit the development of atopic dermatitis (AD). To identify the effect of K284, we used phthalic anhydride (5% PA)-induced AD animal model and in vitro reconstructed human skin model. We analyzed the expression of AD-related cytokine mediators and NF-κB signaling by Western blotting, ELISA and quantitative real-time PCR. Histological analysis showed that K284 treatment suppressed PA-induced epidermal thickening and infiltration of mast cells. K284 treatment also reduced PA-induced release of inflammatory cytokines. In addition, K284 treatment inhibited the expression of NF-κB activity in PA-treated skin tissues and TNF-α and IFN-γ-treated HaCaT cells. Protein-association network analysis indicated that CHI3L1 is associated with lactoferrin (LTF). LTF was elevated in PA-treated skin tissues and TNF-α and IFN-γ-induced HaCaT cells. However, this expression was reduced by K284 treatment. Knockdown of LTF decreased the expression of inflammatory cytokines in TNF-α and IFN-γ-induced HaCaT cells. Moreover, anti-LTF antibody treatment alleviated AD development in PA-induced AD model. Our data demonstrate that CHI3L1 targeting K284 reduces AD-like skin inflammation and K284 could be a promising therapeutic agent for AD by inhibition of LTF expression.

• Proceedings of the KSAR Conference
• /
• 2003.06a
• /
• pp.54-54
• /
• 2003

The activation of protooncogenes or the inactivation of their gene products may be a specific and effective functional study for human neoplasia. To examine this possibility, we have used the tetracycline regulatory system to generate transgenic mice that conditionally express the HccR-2 protooncogene in vivo. The new human cervical cancer protooncogene (HccR-2) was detected from cervical cancer cell line. To elucidate its biological functions, we generated transgenic mice that expressed the HccR-2 gene. The sustained expression of the HccR-2 transgene culminated chronic neutrophilic leukemia (CNL). CNL is a rare chronic myeloproliferative disorder that presents as a sustained, mature neutrophilic leukocytosis with few or no circulating immature granulocytes, the absence of peripheral blood monocytosis, basophilia, or eosinophilia, and infiltration of neutrophils at the liver, spleen and kidney. Mice expressing the HccR-2 and tetracycline-transactivating protein (tTa) transgene were found to have altered myeloid development that was characterized by increased percentages of mature neutrophil and band form neutrophil in the peripheral blood, liver and spleen. Activation of the transgene causes CNL. In our model, expression of HccR-2 transgene mice was similar in many respects to the human CNL. This model will be valuable not only for investigating the biological properties of the HccR-2 and other protooncogenes in vivo but also for analyzing the mechanism involved in the progression of CNL.

• Quality Improvement in Health Care
• /
• v.12 no.2
• /
• pp.113-123
• /
• 2006

Objective : This research is focused on understanding the current status of the Health Smart Card already in use in other advanced countries. This research will analyze the current status of the medical institutions Health Smart Card system adoption process and its effects, and provide a basis for future policy decisions for the effective adoption and diffusion of a Health Smart Card system, in the medical field, through the completed research and analysis. Method : This research surveys the domestic, and foreign, status of Health Smart Card usage. The research also presents up-to-date methodology for the evaluation of the effects of medical and health care technology. The research also conducts a survey of the domestic medical institutions that have implemented a Health Smart Card system, and then analyzes the results of the survey. Additionally, the research carried out a survey and analysis of medical institutions with no Health Smart Card system implemented, and considered the factors affecting the diffusion of Health Smart Card systems in considering an effective policy for the introduction and diffusion of such a system. Research Results : Through the study of the methodology of medical and health care information technology in advanced countries, the methodology for assessing Health Smart Card technology has been established, and focuses on 6 aspects. The study on the status of foreign implementation has shown a model for the Health Smart Card system. A survey was conducted on the current status of medical institutions with an implemented Health Smart Card system, and the survey results have been analyzed. Also, factors influencing the adoption of Health Smart Card systems have been analyzed through the survey on those medical institutions that have not implemented a Health Smart Card system. Conclusion : The government must provide institutional measures for sharing medical records by constructing an IT infrastructure at the national level to enable the adoption and diffusion of a Health Smart Card system. Such a network will make connections between medical institutions possible, thus making the diffusion of the Health Smart Card system nationwide. For the successful adoption and diffusion of a Health Smart Card system, a model system development, under a medical record sharing system, should be conducted. Additionally, a regional unit based model should be developed for the model project, as is done in advanced countries, along with the application of such results.

• Journal of the Korea Convergence Society
• /
• v.13 no.3
• /
• pp.67-75
• /
• 2022

Medical information is variously generated not only from medical devices but also from electronic devices. Recently, related convergence technologies from big data collection in healthcare to medical AI products for patient's condition analysis are rapidly increasing. However, there are difficulties in applying them because of independent developmental procedures. In this paper, we propose an intelligent hospital information system (iHIS) model to simplify and integrate research, development and application of medical AI technology. The proposed model includes (1) real-time patient data management, (2) specialized data management for medical AI development, and (3) real-time monitoring for patient. Using this, real-time biometric data collection and medical AI specialized data generation from patient monitoring devices, as well as specific AI applications of camera-based patient gait analysis and brain MRA-based cerebrovascular disease analysis will be introduced. Based on the proposed model, it is expected that it will be used to improve the HIS by increasing security of data management and improving practical use through consistent interface platformization.

• Research in Community and Public Health Nursing
• /
• v.8 no.2
• /
• pp.314-326
• /
• 1997

In Korea, the nosocomial infection control program is not well developed. This situation is created by a lack of interest from medical personnel and the medical payment system. This study identifies current problems and develops a model for nosocomial infection control. The studies of Lee & Kim(1995), Lee (1993) and SENIC project model were used to construct this model. 1. The problems of nosocomial infection control were identified as the following: dis approval by hospital authorities, lack of sources for program direction, lack of overall structure and function in the program, inadequate direct action, lack of education and training, and so on. 2. The problems are reorganized according to the 5 elements of system theory. 3. As a result, the new nosocomial infection control model was developed. The inputs of the model were the elements, resources and boundaries of nosocomial infection. With the new model, each hospital can evaluate their current programs and plan a new program for the better control of nosocomial infection.

• Translational and Clinical Pharmacology
• /
• v.26 no.3
• /
• pp.115-117
• /
• 2018

This tutorial explains the basic principles of mechanistic ligand-receptor interaction model, which is an operational model of agonism. A growing number of agonist drugs, especially immune oncology drugs, is currently being developed. In this tutorial, time-dependent ordinary differential equation for simple $E_{max}$ operational model of agonism was derived step by step. The differential equation could be applied in a pharmacodynamic modeling software, such as NONMEM, for use in non-steady state experiments, in which experimental data are generated while the interaction between ligand and receptor changes over time. Making the most of the non-steady state experimental data would simplify the experimental processes, and furthermore allow us to identify more detailed kinetics of a potential drug. The operational model of agonism could be useful to predict the optimal dose for agonistic drugs from in vitro and in vivo animal pharmacology experiments at the very early phase of drug development.

• 대한핵의학회:학술대회논문집
• /
• 1999.11a
• /
• pp.28.2-28.2
• /
• 1999

• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.10a
• /
• pp.864-865
• /
• 2005

• Journal of the Korean Institute of Electrical and Electronic Material Engineers
• /
• v.24 no.6
• /
• pp.519-524
• /
• 2011

ABLB (alternate binaural loudness balance) test is one of the medical assessments to diagnose detailed lesion of sensory-neural hearing loss based on a recruitment phenomenon. However, current ABLB audiometry takes an operational model, so called face-to-face model, in which model one audiometrist can assess only one subject at a time. As a result, this face-to-face model leads to expensive audiometrist's labor cost and lengthy wait when there exist many subjects. As a solution, this paper suggests an ABLB audiometry system supporting one-to-many model in which model an audiometrist enables to assess several subjects concurrently. By providing such capabilities as real-time transfer of assessment result, video monitoring of subject and video chat, this solution can provide same effect as face-to-face model but overcome weakness of the existing face-to-face model.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.18
• /
• pp.7713-7718
• /
• 2014

Background: Despite evidence suggesting roles for caspase-8 (CASP8) -652 6N del and D302H polymorphisms in prostate cancer (PCa), the association of these polymorphisms with PCa risk remains inconclusive. Therefore, a meta-analysis was performed to more precisely estimate the association of CASP8 -652 6N del and D302H polymorphisms with PCa susceptibility. Materials and Methods: A comprehensive literature search was conducted to identify all case-control studies of CASP8 D302H and -652 6N del polymorphisms and PCa risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association and the precision of the estimate, respectively. Results: Nine -625 6N del studies and 4 D302H studies were included. CASP8 -652 6N del and D302H polymorphisms were not significantly associated with PCa risk in the overall analyses. However, in the subgroup analysis stratified by ethnicity, -625 6N del was significantly associated with PCa risk in the East Asian and Indian populations under the recessive model. Furthermore, the subgroup analysis strongly suggested that D302H was associated with lower PCa risk in the Non-Indian population under the dominant model. Conclusions: In our meta-analysis, ethnic-specific differences were evident in the association of CASP8-625 6N del and D302H polymorphisms with PCa risk.